



BIOVISION The World Life Sciences Forum

Biovision Investor Conference 13-14 APRIL 2016



ANTABIO SAS



One line pitch:

Antabio is a private company, dedicated to the discovery of game-changing treatments of life-threatening and drug-resistant bacterial infections.

Market Analysis:

Antibiotic resistance is a growing global health problem recognized as n°1 priority by the WHO. 5-10% of hospital patients in US and Europe develop a hospital-acquired (nosocomial) infection with annual > €30 billion additional costs to public health and > 100,000 deaths due to drug-resistant bacterial infections. Antabio's breakthrough products are addressing worldwide premium-price commanding markets and expected to reach \$10 billion cumulated sales per product with peak sales over \$1 billion and treatment prices between 20 and 30k\$.

Business Proposition:

Antabio focuses on the development of new combination and/or adjunctive antibiotic therapies, whereby small molecule compounds targeting key bacterial resistance and pathogenicity mechanisms are coadministered with antibiotics to enhance their effectiveness. These programs address areas of highest unmet needs such as infections caused by multi-drug resistant Gram-negative pathogens for which there are no available treatments, e.g. MBL producer superbugs currently spreading worldwide and chronic Pseudomonas biofilms (PB) responsible for early death of cystic fibrosis patients.

Competitive Advantage:

Antabio's MBL inhibitor has a broad MBL coverage including VIM and NDM types. Due to its simple chemical structure the COG is expected to be low and its combination with the proven, clinically effective carbapenem, meropenem, means that the product should receive wide acceptance. Antabio's PB inhibitor is offering enhanced antibiotic therapy against chronic Pseudomonas infections that are difficult to kill with current antibiotics. Used in combination with inhaled tobramycin the product will have wide clinical acceptance and is expected to replace TOBI® (Novartis) as the new standard-of-care.

Investment Attractiveness:

Antabio has a rich portfolio of first-in-class programs addressing major gaps in the antibacterial pipeline and tackling the highest unmet needs in the antibacterial space. The company has earned the support from the Wellcome Trust in 2 active funded programs. Antabio has an expert international antibacterial team, with specific expertise in the discovery and development of inhibitors of clinically-relevant bacterial metallo-enzymes (such as the NDM-1 metallo beta-lactamase). Antabio is seeking €15 million investment now to advance our first leads beyond phase 1, an early de-risking step for antibacterial drugs.

IP Situation:

Antabio pursues an aggressive IP strategy to protect its drug discovery portfolio through novel composition of matter claims on selected series and claims on use of the compounds. The company currently has 6 families of patents covering 4 different areas. The 2 lead programmes, MBL inhibitors and PB inhibitors, are respectively protected by PCT/EP2014/062281 and UK 1422047.9 (11/12/14, pending); and UK 1422489.3 (17/12/14, pending).

COMPANY PROFILE

- **Website:**
www.antabio.com
- **Activity:** Biotech
- **Contact:**
Lemonnier Marc
info@antabio.com
- **Location:**
Biostep 436 Rue Pierre et Marie Curie
31670
France
- **Founded in:** 15/10/2009
- **Employees:** 13
- **Management:**
Lemonnier Marc
CEO
Dugray Aymeric
CFO
Davies David
Head of Medicinal Chemistry
Everett Martin
Head of Biology
- **Financial information (€):**
 - **Company stage:**
Discovery
 - **Capital raised to date:**
€12 million
 - **Monthly burn rate:**
 - **Capital seeking and date:**
€15 million by June 2016
- **Investors:**
- **Referred by:**
Laurence Bougnères-Vermont,
Auriga Partners